Pharma Giants Rush to Expand US Output as Trump Tariff Threat Reshapes Industry Modern Diplomacy
Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Modern Diplomacy.
The global next generation drug conjugates (NGDC) market is projected to grow from USD 15.75 billion in 2026 to USD 42.55 billion by 2035, representing a compound annual growth rate of 11.7%. This expansion is driven by the rising adoption of precision medicine and significant advancements in targeted drug delivery technologies that minimize off-target toxicity. For the pharmaceutical sector, this growth underscores a strategic shift toward biomarker-guided therapies and the diversification of conjugation platforms beyond traditional oncology applications.
June 15, 2026Lifecore Biomedical has entered into a new agreement with a global pharmaceutical company to provide technical transfer and commercial manufacturing services for an injectable suspension product targeting neurological disorders. This partnership marks the company's seventh late-stage program win within a seven-month period, highlighting a significant expansion of its contract development and manufacturing organization (CDMO) pipeline. The deal underscores the pharmaceutical industry's growing demand for specialized U.S.-based manufacturing of high-viscosity and complex formulations.
June 15, 2026The global heart transplantation therapeutics market is valued at USD 1.19 billion in 2025 and is projected to reach USD 1.74 billion by 2034, growing at a CAGR of 4.32%. This growth is primarily driven by the increasing prevalence of end-stage heart failure and the rising demand for advanced immunosuppressive and anti-infective therapies. For the pharmaceutical sector, this expansion highlights a critical shift toward precision medicine and personalized transplant care to improve long-term patient survival and reduce organ rejection.
June 15, 2026The global Fourier Transform Infrared Spectroscopy (FTIR) market is projected to expand at a compound annual growth rate of 4.5% to 6.5% through 2035, largely driven by tightening regulatory frameworks in the pharmaceutical sector. Pharmaceutical and biomedical end users represent the largest market segment, accounting for approximately 35% to 45% of global demand for identity testing and raw material verification. This growth reflects a broader industry shift toward advanced materials characterization and more disciplined procurement behavior across a diversified global supply architecture.
June 15, 2026